Search research articles
Contact Us
Filters
Showing results (171-180 of 241) with videos related to
Page
of 25
Sort By:
Annals of Clinical and Translational Neurology
|
November 5, 2019
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis
Marcel Naumann, Kevin Peikert, Rene Günther, et al.
Journal of Medical Genetics
|
March 23, 2022
A polymorphic AT-repeat causes frequent allele dropout for an <i>MME</i> mutational hotspot exon
Helle Høyer, Hilde T Hilmarsen, Raute Sunder-Plassmann, et al.
Brain : a Journal of Neurology
|
March 7, 2016
NEK1 mutations in familial amyotrophic lateral sclerosis
David Brenner, Kathrin Müller, Thomas Wieland, et al.
Ebiomedicine
|
March 14, 2023
Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers
Johannes Dorst, Patrick Weydt, David Brenner, et al.
European Journal of Neurology
|
March 12, 2024
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)
Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 23, 2015
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
Petra Steinacker, Emily Feneberg, Jochen Weishaupt, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Journal of Neurology
|
May 6, 2018
Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications
Peter M Andersen, Magdalena Kuzma-Kozakiewicz, Jürgen Keller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Human Molecular Genetics
|
January 10, 2018
CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency
Sarah J Brockmann, Axel Freischmidt, Patrick Oeckl, et al.
Page
of 25
Search research articles
Search
Showing results (171-180 of 241) with videos related to
Sort By:
Page
of 25
Annals of Clinical and Translational Neurology
|
November 5, 2019
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis
Marcel Naumann, Kevin Peikert, Rene Günther, et al.
Journal of Medical Genetics
|
March 23, 2022
A polymorphic AT-repeat causes frequent allele dropout for an <i>MME</i> mutational hotspot exon
Helle Høyer, Hilde T Hilmarsen, Raute Sunder-Plassmann, et al.
Brain : a Journal of Neurology
|
March 7, 2016
NEK1 mutations in familial amyotrophic lateral sclerosis
David Brenner, Kathrin Müller, Thomas Wieland, et al.
Ebiomedicine
|
March 14, 2023
Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers
Johannes Dorst, Patrick Weydt, David Brenner, et al.
European Journal of Neurology
|
March 12, 2024
European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)
Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 23, 2015
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
Petra Steinacker, Emily Feneberg, Jochen Weishaupt, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 29, 2022
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Journal of Neurology
|
May 6, 2018
Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications
Peter M Andersen, Magdalena Kuzma-Kozakiewicz, Jürgen Keller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
May 18, 2022
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar, Joanne Wuu, Peter M Andersen, et al.
Human Molecular Genetics
|
January 10, 2018
CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency
Sarah J Brockmann, Axel Freischmidt, Patrick Oeckl, et al.
Page
of 25